Nobiletin treatment along with p53 siRNA furthermore inhibited the expression of p53, pMDM2, and PD-L1, along with unchanged total MDM2 expressions in NSCLC cells (Figure 5B). The gene discussed is TP53; the disease is non-small cell lung carcinoma.